Safety and Effect of Oral Doses of 5mg or 10mg of SLx-2101 for 14 Days in Patients With Hypertension

• Status: Completed
• Trial end date: 2007-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose is to determine the effect of SLx-2101 dosed at 5mg or 10mg for 14 days on systolic, diastolic pressures and heart rate in patients with hypertension.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Kadmon Corporation, LLC

Criteria

Inclusion Criteria:

• Male or female subjects between 18 and 70 years old, inclusive

• Moderate to severe hypertension

• Body weight within a body mass index of 18-32kg/m2

Exclusion Criteria:

• The subject is receiving more than three antihypertensive agents

• A history of drug abuse

• Exposure to a new chemical entity within 3 months prior to the first day of dosing